Literature DB >> 29893210

Psoriatic arthritis: novel targets add to a therapeutic renaissance.

Peter Nash1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29893210     DOI： 10.1016/S0140-6736(18)31217-0

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  2 in total

1.  Disease interception with interleukin-17 inhibition in high-risk psoriasis patients with subclinical joint inflammation-data from the prospective IVEPSA study.

Authors:  Eleni Kampylafka; David Simon; Isabelle d'Oliveira; Christina Linz; Veronika Lerchen; Matthias Englbrecht; Juergen Rech; Arnd Kleyer; Michael Sticherling; Georg Schett; Axel J Hueber
Journal:  Arthritis Res Ther       Date:  2019-07-26       Impact factor: 5.156

2.  Secukinumab leads to shifts from stage-based towards response-based disease clusters-comparative data from very early and established psoriatic arthritis.

Authors:  Eleni Kampylafka; Koray Tascilar; Veronika Lerchen; Christina Linz; Maria Sokolova; Ana Zekovic; Arnd Kleyer; David Simon; Jürgen Rech; Michael Sticherling; Georg Schett; Axel J Hueber
Journal:  Arthritis Res Ther       Date:  2020-09-09       Impact factor: 5.156
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.